JPH0114206B2 - - Google Patents
Info
- Publication number
- JPH0114206B2 JPH0114206B2 JP54109837A JP10983779A JPH0114206B2 JP H0114206 B2 JPH0114206 B2 JP H0114206B2 JP 54109837 A JP54109837 A JP 54109837A JP 10983779 A JP10983779 A JP 10983779A JP H0114206 B2 JPH0114206 B2 JP H0114206B2
- Authority
- JP
- Japan
- Prior art keywords
- antithrombotic agent
- extract
- platelet
- extracts
- antithrombotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003146 anticoagulant agent Substances 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 229960004676 antithrombotic agent Drugs 0.000 claims description 16
- 241000411851 herbal medicine Species 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 241000218671 Ephedra Species 0.000 claims description 6
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 241000219063 Rheum rhabarbarum [NCBITaxon:3621] Species 0.000 claims 1
- 241000750631 Takifugu chinensis Species 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 10
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10983779A JPS5632418A (en) | 1979-08-28 | 1979-08-28 | Antithrombic agent containing crude drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10983779A JPS5632418A (en) | 1979-08-28 | 1979-08-28 | Antithrombic agent containing crude drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5632418A JPS5632418A (en) | 1981-04-01 |
| JPH0114206B2 true JPH0114206B2 (xx) | 1989-03-10 |
Family
ID=14520454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10983779A Granted JPS5632418A (en) | 1979-08-28 | 1979-08-28 | Antithrombic agent containing crude drug |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5632418A (xx) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62244930A (ja) * | 1986-04-15 | 1987-10-26 | Kubota Ltd | フロントロ−ダの制御装置 |
| US4982009A (en) * | 1990-01-31 | 1991-01-01 | E. I. Du Pont De Nemours And Company | Hydroxy containing fluorovinyl compounds and polymers thereof |
| US5059720A (en) * | 1990-01-31 | 1991-10-22 | E. I. Du Pont De Nemours And Company | Hydroxy containing fluorovinyl compounds and polymers thereof |
| US5531991A (en) * | 1994-05-04 | 1996-07-02 | The Board Of Regents Of Oklahoma State University | Composition and method for treating hyperglycemia utilizing an extract of Polygonum multiflorum |
| US6238675B1 (en) | 1997-02-27 | 2001-05-29 | Campamed Corp. | Method of preparation and composition of a water soluble extract of the plant species Uncaria for enhancing immune, anti-inflammatory and anti-tumor processes of warm blooded animals |
| US6361805B2 (en) | 1997-02-27 | 2002-03-26 | Ronald W. Pero | Method of preparation and composition of a water soluble extract of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals |
| US6039949A (en) * | 1997-02-27 | 2000-03-21 | Campamed, Inc. | Method of preparation and composition of a water soluble extract of the plant species uncaria |
| KR20010077956A (ko) * | 2000-02-08 | 2001-08-20 | 배석태 | 하수오에서 항산화 성분을 추출하는 방법, 하수오 추출물및 하수오 추출물 또는 하수오 분말을 포함하는 건강식품 |
| KR100362940B1 (ko) * | 2002-05-17 | 2002-11-30 | 한국과학기술연구원 | 헤마테인을 함유하는 고지혈증 및 동맥경화증 예방 및치료용 조성물 |
| CN1692914B (zh) * | 2004-04-29 | 2010-05-26 | 中国人民解放军军事医学科学院放射医学研究所 | 知母皂苷bⅱ在制备用于防治脑卒中药物或产品中的用途 |
| GB201223365D0 (en) * | 2012-12-24 | 2013-02-06 | Provexis Natural Products Ltd | Compositions |
-
1979
- 1979-08-28 JP JP10983779A patent/JPS5632418A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5632418A (en) | 1981-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6855734B2 (en) | Glycine betaine and its use | |
| JPH0813742B2 (ja) | 血液凝固阻止剤 | |
| CN106214674B (zh) | 7-羟基-丁苯酞的医药用途 | |
| JPH0114206B2 (xx) | ||
| CN102665747A (zh) | 含有三桠乌药提取物作为有效成分的改善血液循环的组合物 | |
| WO2013189285A1 (zh) | 曲札茋苷在制备改善微循环障碍药物中的应用 | |
| CN104774243A (zh) | 一种麒麟菜多肽提取物及其制备方法和应用 | |
| JPS60109524A (ja) | 抗血栓剤 | |
| JP2013503821A (ja) | 血栓症に対処するための医薬組成物、ならびにその調製方法および使用 | |
| CN103908460B (zh) | 三七皂苷Fc的医药用途 | |
| CN114469910B (zh) | 马醉木苷元在制备抗血栓药物中的应用 | |
| KR100740326B1 (ko) | 두통 치료의 약제 조성물 및 그 제조방법과 응용 | |
| KR20200062784A (ko) | 발효마늘을 함유하는 항혈전 조성물 | |
| JPS626687B2 (xx) | ||
| Cantón et al. | In vitro and in vivo antiaggregant effects of magnesium halogenates | |
| CN113116885A (zh) | 一种茶多酚类化合物在制备抗血栓药物中的应用 | |
| CN106822090B (zh) | 3,4,7-三羟基异黄酮或3-甲氧基大豆素在制备抑制血小板聚集和血栓药物中的应用 | |
| CN103417565B (zh) | 解聚海参糖胺聚糖在制备防治血栓性疾病药物中的应用 | |
| RU2806093C1 (ru) | Применение икаритина для получения лекарственных средств | |
| CN106344634B (zh) | 一种芒果皮提取物及其制备方法和用途 | |
| CN114390927A (zh) | 一种中药组合物的新用途 | |
| JPS629567B2 (xx) | ||
| CN113244225B (zh) | 土槿皮乙酸在制备抗血小板药物中的应用 | |
| US20230103858A1 (en) | Medical use of icaritin | |
| JPS6045529A (ja) | 抗血栓症剤 |